LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD.

Luoxin Pharmaceuticals Group Stock Co., Ltd.

002793

CNE1000026S7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
4.32 ^CNY	-0.46%		+6.93%	-19.40%

Apr. 26	Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 08	Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology	MT

Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024.

February 19, 2024 at 11:00 am EST

From February 1, 2024 to February 8, 2024, the company has repurchased 26,027,861 shares, representing 2.39% for CNY 99.99 million. With this, the company has completed the repurchase of 26,027,861 shares, representing 2.39% for CNY 99.99 million under the buyback announced on February 2, 2024.

Latest news about Luoxin Pharmaceuticals Group Stock Co., Ltd.

Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology	Mar. 08	MT
Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024.	Feb. 19	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback announced on February 2, 2024, has closed with 26,027,861 shares, representing 2.39% for CNY 99.99 million.	Feb. 07	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	Feb. 01	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. authorizes a Buyback Plan.	Jan. 31	CI
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial	Jan. 29	MT
Two Luoxin Pharma Drugs Selected in China’s National Drug Procurement Program	Nov. 17	MT
Luoxin Health Technology Development Co., Ltd. announced that it has received CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.	Nov. 16	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023	23-10-23	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. agreed to acquire additional unknown stake in Luoxin Health Technology Development Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP) and Deyi Investment Management Co., Ltd. for CNY 1.	23-10-13	CI
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.	23-10-12	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Li Meng as Non-Independent Directors	23-02-01	CI
Luoxin Pharmaceuticals' Injection Passes Regulatory Consistency Evaluation	23-01-11	MT
Luoxin Pharmaceuticals Gets Regulatory Nod for Anti-Baterial Infection Drug	22-12-28	MT
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Luoxin Pharmaceuticals Unit Plans to Sell Stake in Medical Equipment Firm	22-09-21	CI
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 127.9 million in funding from Deyi Investment Management Co., Ltd., Luoxin Pharmaceuticals Group Stock Co., Ltd.	22-09-13	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
HK inno.N's Gastroesophageal Reflux Disease Drug Gets Marketing Approval in China	22-04-17	MT

Chart Luoxin Pharmaceuticals Group Stock Co., Ltd.

Duration

Period

Chart Luoxin Pharmaceuticals Group Stock Co., Ltd.

More charts

Company Profile

Luoxin Pharmaceuticals Group Stock Co Ltd, formerly Zhejiang Doyin Pump Industry Co Ltd, is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates two segments. The Pharmaceutical Industry segment is engaged in the research and development, manufacturing and sales of chemical drug preparations and raw and auxiliary drugs. Its main products are digestive drugs, respiratory drugs and antibiotic drugs, among others. The Pharmaceutical Business segment is engaged in the sales and logistics of agent drugs and medical devices. The Company conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD.	-19.40%	648M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B